Device Trial Radar · NCT04837651
Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab
Last checked: Nov 20, 2026Latest source record: Aug 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Mar 2, 2021
Primary completion
Jul 1, 2021
Study completion Jul 1, 2021
Sponsor
- Lead sponsor
- Dragonfly Research, LLCAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 8, 2021
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary goal of this study is to provide additional data regarding B and T-cell mediated responses to COVID-19 vaccines in MS patients treated with OCR and to determine which clinical and paraclinical variables correlating with vaccine immunogenicity. B-cell mediated humoral responses and adaptive T-cell mediated cellular responses were measured in patients treated with OCR who received any of the available SARS-CoV-2 vaccines, 3-4 weeks after completion of vaccination.
Conditions
- Multiple Sclerosis
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Nervous System Diseases
- Demyelinating Diseases
- Autoimmune Diseases
- Immune System Diseases
- Pathologic Processes
Interventions
Elecsys semi-quantitative Anti-SARS-CoV-2 antibody testDevice
Subjects will receive an Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test within 4 weeks of receiving their first COVID-19 injection. Within 3-4 weeks of receipt of their final COVID-19 vaccine dose, subjects will receive another Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test.
T-Detect COVID T-cell blood testDevice
A select number of subjects will also receive a qualitative SARS-CoV-2 t-cell immunity test, the T-Detect COVID test, within 3-4 weeks of receipt of their final COVID-19 vaccine dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SARS-CoV-2 B-cell responseTime frame: Measured within 3-4 weeks of final COVID-19 vaccine dose
- SARS-CoV-2 T-cell responseTime frame: Measured within 3-4 weeks of final COVID-19 vaccine dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dragonfly Research, LLC
Wellesley, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.